Comparative proteomic analysis of circulating tumor exosomes in human saliva and serum for lung cancer
演讲题目:Comparative proteomic analysis of circulating tumor exosomes in human saliva and serum for lung cancer
演讲题目：Comparative proteomic analysis of circulating tumor exosomes in human saliva and serum for lung cancer
演讲摘要：Tumor-derived exosomes harbor plenty of cancer biological information, which has emerged as promising targets for cancer early detection and treatment. Human serum and saliva are unique diagnostic body fluids, which contain numerous circulating exosomes. Salivary and serum exosomes were enriched through commercial kit after high abundant protein removal. They were further confirmed by morphology analysis, nanoparticle tracking analysis, and surface biomarker test. Label free quantification was applied to systematically compare the protein profiling in salivary and serum exosomes. Their similarities and differences were systematically compared for the first time. 319 and 994 exosomal proteins were identified from saliva and serum by LC-MS/MS, respectively. Around 80% of salivary exosomal proteins were shared with serum exosomes. To explore their utility for cancer proteomics, we systematically compared the proteome of salivary and serum exosomes from healthy subjects and lung cancer patients. In particular, 11 potential candidates were coincidently discovered in both body fluids of lung cancer patients. Selected 6 exosomal protein candidates were further verified and evaluated through immunoassay. We further isolated microvesicles and exosomes in human saliva and comprehensively analyzed their proteome. 40 and 25 potential proteins originally from distal cells were found in the circulating salivary microvesicles and exosomes of lung cancer subjects. Our finding enforced the hypothesis that cancer related proteins were presented in saliva and serum exosomes, which promoted the unique features of exosomes in our body fluids. A circulating exosomes based body fluid test could be easily established for monitoring cancer once these candidates were validated.